Trial Profile
Abciximab in Emergent Stroke Treatment Trial - II
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2009
Price :
$35
*
At a glance
- Drugs Abciximab (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms AbESTT-II
- 01 Dec 2008 Results published in Stroke.
- 01 Jan 2008 Results have been published.
- 21 Oct 2005 New trial record.